PRESS RELEASE: CMS assigns new technology payment classification for Optellum’s Lung Cancer Prediction score

This payment assignment to a newly available Healthcare Common Procedure Coding System (HCPCS) code constitutes an important step towards reimbursing providers for the use of Optellum’s transformative technology with Medicare…

Continue ReadingPRESS RELEASE: CMS assigns new technology payment classification for Optellum’s Lung Cancer Prediction score

Optellum’s UK regulatory certification bolstered by UKCA marking for its early lung cancer diagnosis AI technology

After gaining CE certification for its software Virtual Nodule Clinic, Optellum has attained UKCA certification under the UK’s Medical Devices Regulations. Optellum, an Oxford-based medtech company, provides breakthrough AI technologies…

Continue ReadingOptellum’s UK regulatory certification bolstered by UKCA marking for its early lung cancer diagnosis AI technology

PRESS RELEASE: Optellum attains CE marking for its early lung cancer diagnosis AI technology

Optellum Virtual Nodule Clinic, including its proprietary artificial intelligence lung cancer prediction solution, has achieved CE certification under the European Union’s Medical Device Regulation. Oxford, UK – 30 March 2022:…

Continue ReadingPRESS RELEASE: Optellum attains CE marking for its early lung cancer diagnosis AI technology

Optellum recognised by the NHS and Health Education England and included as one of two case studies in AI Roadmap report

Optellum is referenced within the report with recommendations on how AI will be implemented and physicians trained in new technologies across the NHS Optellum has been named as one of…

Continue ReadingOptellum recognised by the NHS and Health Education England and included as one of two case studies in AI Roadmap report

PRESS RELEASE: GE Healthcare and Optellum Join Forces to Advance Lung Cancer Diagnosis with Artificial Intelligence

Oxford, UK/Chalfont St Giles 26 November 2021 13:00 GMT - GE Healthcare and Optellum today announced that they have signed a letter of intent to collaborate to advance precision diagnosis…

Continue ReadingPRESS RELEASE: GE Healthcare and Optellum Join Forces to Advance Lung Cancer Diagnosis with Artificial Intelligence

PRESS RELEASE: Optellum Appoints Jason Pesterfield as CEO to Drive Commercial Growth in the USA

Fast-growing lung-health AI startup strengthens executive team with business leader experienced in medical devices for lung cancer diagnosis. Jason Pesterfield was previously CEO at Veran Medical Technologies, growing it through…

Continue ReadingPRESS RELEASE: Optellum Appoints Jason Pesterfield as CEO to Drive Commercial Growth in the USA

PRESS RELEASE: Optellum Announces Strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson, Applying AI to Transform Early Lung Cancer Treatment

Rapidly growing lung health startup aims to redefine early interception of lung cancer using artificial intelligence (AI) decision support software. OXFORD, UK / HOUSTON, USA – August 18, 2021: Optellum,…

Continue ReadingPRESS RELEASE: Optellum Announces Strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson, Applying AI to Transform Early Lung Cancer Treatment

AI software could help clinicians diagnose lung cancer earlier and reduce waiting lists for patients

A new artificial intelligence software that will help doctors to make quicker and more accurate decisions when diagnosing potentially cancerous lung lesions, has received major government funding. This is a…

Continue ReadingAI software could help clinicians diagnose lung cancer earlier and reduce waiting lists for patients

European consortium validates Optellum AI to differentiate between benign and malignant lung nodules in a multi-center study

A paper published in Lung Cancer demonstrates the ability of Optellum’s Lung Cancer Prediction artificial intelligence (AI) to classify lung nodule malignancy. As discussed in earlier news stories, there has…

Continue ReadingEuropean consortium validates Optellum AI to differentiate between benign and malignant lung nodules in a multi-center study